Evidence map›Paper›PMID 38312790›Full record

ArticleKidney international reports2024

Improved Renal Function in Initial Treatment Improves Patient Survival, Renal Outcomes, and Glucocorticoid-Related Complications in IgG4-Related Kidney Disease in Japan.

Ichiro Mizushima, Takako Saeki, Daisuke Kobayashi, Naoki Sawa, Hiroki Hayashi, Yoshinori Taniguchi, Hirosuke Nakata, Kazunori Yamada, Shoko Matsui, Tetsuhiko Yasuno and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 1 country.

Ichiro MizushimaDepartment of Rheumatology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
Takako SaekiDepartment of Internal Medicine, Nagaoka Red Cross Hospital, Nagaoka, Japan.
Daisuke KobayashiDivision of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Japan.
Naoki SawaDepartment of Nephrology Center, Toranomon Hospital, Kawasaki, Japan.
Hiroki HayashiDepartment of Nephrology, Fujita Health University School of Medicine, Toyoake, Japan.
Yoshinori TaniguchiDepartment of Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi University, Nankoku-shi, Japan.
Hirosuke NakataDepartment of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto City, Japan.
Kazunori YamadaDepartment of Hematology and Immunology, Kanazawa Medical University, Kahoku-gun, Japan.
Shoko MatsuiHealth Administration Center, University of Toyama, Toyama City, Japan.
Tetsuhiko YasunoDivision of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fukuoka University, Jonan-Ku, Japan.
Kosuke MasutaniDivision of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fukuoka University, Jonan-Ku, Japan.
Tasuku NagasawaDivision of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Hospital, Sendai, Japan.
Hiroki TakahashiDepartment of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Yoshifumi UbaraDepartment of Nephrology Center, Toranomon Hospital, Kawasaki, Japan.
Motoko YanagitaDepartment of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto City, Japan.
Mitsuhiro KawanoDepartment of Rheumatology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
Fukuoka University · JPKanazawa University · JPKyoto University · JPToranomon Hospital · JPFujita Health University · JPKanazawa Medical University · JPKōchi University · JPNagaoka Red Cross Hospital · JPNiigata University · JPSapporo Medical University · JPTohoku University Hospital · JPUniversity of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: We aimed to clarify long-term renal prognosis, complications of malignancy, glucocorticoid (GC) toxicity, and mortality in immunoglobulin G4 (IgG4)-related kidney disease (IgG4-RKD). Methods: Reviewing the medical records of 95 patients with IgG4-RKD, we investigated clinical and pathologic features at baseline, the course of renal function, complications of malignancy, GC toxicity, and mortality during follow-up (median 71 months). The standardized incidence ratio (SIR) of malignancy and standardized mortality ratio were calculated using national statistics. Factors related to outcomes were assessed by Cox regression analyses. Results: At diagnosis, the median estimated glomerular infiltration rate (eGFR) was 46 ml/min per 1.73 m Conclusion: This study suggests that more renal function recovery through early treatment initiation may improve patient survival, renal outcomes, and some GC-related complications in IgG4-RKD.

Indexed as

deathglucocorticoidIgG4-related kidney diseasemalignancyoutcometreatment

Identifiers

PMID38312790
PMCPMC10831353
OpenAlexW4387806554

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.